Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of ...
Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of ...
DURHAM, N.C. – Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma ...
Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback